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The incorporation of genomics into medicine is stimulating interest on the return of incidental findings (IFs) from exome and
genome sequencing. However, no large-scale study has yet estimated the number of expected actionable findings per individual;
therefore, we classified actionable pathogenic single-nucleotide variants in 500 European- and 500 African-descent participants
randomly selected from the National Heart, Lung, and Blood Institute Exome Sequencing Project. The 1,000 individuals were screened
for variants in 114 genes selected by an expert panel for their association with medically actionable genetic conditions possibly un-
diagnosed in adults. Among the 1,000 participants, 585 instances of 239 unique variants were identified as disease causing in the Hu-
man Gene Mutation Database (HGMD). The primary literature supporting the variants’ pathogenicity was reviewed. Of the identified
IFs, only 16 unique autosomal-dominant variants in 17 individuals were assessed to be pathogenic or likely pathogenic, and one
participant had two pathogenic variants for an autosomal-recessive disease. Furthermore, one pathogenic and four likely pathogenic
variants not listed as disease causing in HGMD were identified. These data can provide an estimate of the frequency (~3.4% for Eu-
ropean descent and ~1.2% for African descent) of the high-penetrance actionable pathogenic or likely pathogenic variants in adults.
The 23 participants with pathogenic or likely pathogenic variants were disproportionately of European (17) versus African (6) descent.
The process of classifying these variants underscores the need for a more comprehensive and diverse centralized resource to provide
curated information on pathogenicity for clinical use to minimize health disparities in genomic medicine.Introduction
As whole-genome and -exome tests are incorporated
into medicine, the resources required for the return
of genomic incidental findings (IFs) must be
explored. The American College of Medical Genetics
and Genomics (ACMG) has recently recommended
return of IFs from a minimum set of actionable genes.1
However, no large-scale study to date has addressed the
likelihood of identifying pathogenic mutations in
actionable genes per individual or the time burden on
health-care professionals to make these determinations.
These data can inform the policy discussion. We
reviewed the primary literature for possible actionable
pathogenic single-nucleotide variants in 500 European-
and 500 African-descent participants randomly selected
from the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project (ESP). These 1,000
individuals were screened for variants in a list of 114
genes associated with medically actionable genetic condi-
tions that might remain undiagnosed in adults; these
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ACMG.Material and Methods
Development of the Gene List
The gene list and criteria for data supporting the call of a known
highly penetrant pathogenic variant for return were developed
and agreed upon unanimously by the Clinical Sequencing
and Exploratory Research (CSER) ‘‘NEXT Medicine’’ Return of
Results Committee (RORC), funded by the University of Wash-
ington and National Human Genome Research Institute. The
NEXT Medicine RORC comprises 24 experts with a combined
340 clinician years of medical genetics practice and includes 14
practicing clinical medical geneticists, two genetic counselors,
and several other physician and nonphysician members with
expertise in a variety of genetic specialties, including pediatric,
adult, cancer, dermatologic, collagen, neurological, biochemical,
cytogenetic, and molecular diagnostics. ‘‘Actionable’’ genes in
adults were defined as having deleterious mutation(s) whose
penetrance would result in specific, defined medical recommen-
dation(s) both supported by evidence and, when implemented,
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Table 1. Genes with Actionable Variants
Dominant Dominant (cont.) Dominant (cont.) Dominant (cont.) X-Linked Recessive
ACTA2a (102620) FLCN (607273) MYH11 (160745) SCN5A (600163) DMD (300377) ATP7B (606882)
ACTC1 (102540) GCH1 (600225) MYH7 (160760) SDHAF2 (613019) EMD (300384) BCHE (177400)
ACVRL1 (601284) GPD1L (611778) MYL2 (160781) SDHB (185470) GLA (300644) BLM (604610)
APC (611731) HCN4 (605206) MYL3 (160790) SDHC (602413) OTC (300461) CASQ2 (114251)
BMPR1A (601299) HMBS (609806) MYLK (600922) SDHD (602690) - COQ2 (609825)
BRCA1 (113705) KCNE1 (176261) NF2 (607379) SERPINC1 (107300) - COQ9 (612837)
BRCA2 (600185) KCNE2 (603796) PDGFRA (173490) SGCD (601411) - CPT2 (600650)
CACNA1C (114205) KCNE3 (604433) PKP2 (602861) SMAD3 (603109) - F5b (612309)
CACNA1S (114208) KCNH2 (152427) PLN (172405) SMAD4 (600993) - GAA (606800)
CACNB2 (600003) KCNJ2 (600681) PMS2 (600259) SMARCB1 (601607) - HAMP (606464)
CDC73 (607393) KCNQ1 (607542) PRKAG2 (602743) STK11 (602216) - HFEc (613609)
CDH1 (192090) KIT (164920) PRKAR1A (188830) TGFB3 (190230) - HFE2 (602390)
CNBP (116955) LDLR (606945) PROC (176860) TGFBR1 (190181) - IDUA (252800)
COL3A1 (120180) LMNA (150330) PROS1 (176880) TGFBR2 (190182) - LDLRAP1 (605747)
DMPK (605377) MEN1 (613733) PTCH1 (601309) TMEM43 (612048) - PAH (612349)
DSC2 (125645) MET (164860) PTEN (601728) TNNI3 (191044) - PCBD1 (126090)
DSG2 (125671) MLH1 (120436) RBM20 (613171) TNNT2 (191045) - PTS (612719)
DSP (125647) MLH3 (604395) RET (164761) TP53 (191170) - QDPR (612676)
ENG (131195) MSH2 (609309) RYR1 (180901) TPM1 (191010) - SERPINA1 (107400)
EPCAM (185535) MSH6 (600678) RYR2 (180902) TSC1 (605284) - SLC25A13 (603859)
FBN1 (134797) MUTYH (604933) SCN1B (600235) TSC2 (191092) - SLC37A4 (604194)
FH (136850) MYBPC3 (600958) SCN3B (608214) VHL (608537) - SLC7A9 (604144)
MIM numbers are shown in parentheses next to each gene.
aBolded genes are recommended for return by the ACMG guidelines.1
bOnly homozygotes for the F5 c.1601 G>A (pArg534Gln) Factor V Leiden mutation are deemed actionable.3
cOnly homozygotes for the HFE c.845G>A (p.Cys282Tyr) mutation are deemed actionable.3avoidance of significant morbidity. The benefit of intervention
had to be sufficient to counter any concerns raised by an unex-
pected predisposition to disease. Identifying actionable genes to
be included on the IF gene list began with consideration of a
list of ‘‘bin 1’’ genes,2 available clinical tests for genetic disorders,
and genes nominated by group members on the basis of their
clinical expertise. Genes that were unanimously agreed upon
to warrant return upon discovery of a known pathogenic muta-
tion were determined by the committee. Genes that had unclear
associations with disease, for which associated disease treatment
and/or screening had debatable benefit, or for which more
information was required for making a determination were
assigned to group members for evaluation on the basis of interest
or expertise. The list of genes determined to date to have action-
able variants is given in Table 1. The committee continues to
develop and refine this list as new evidence regarding the associ-
ation between genes and disease or actionability becomes avail-
able. Notably, we are developing an actionable-variant database
for an adult population; therefore, only disorders that might
remain undiagnosed in adulthood were included. The impact
on reproductive decision making (e.g., carrier-status reporting)
was not included.632 The American Journal of Human Genetics 93, 631–640, OctoberCriteria for Classification of Variants
The criteria for the classification of highly penetrant pathogenic
variants (Table 2) were meant to be stringent. In the evaluation
process, each variant was classified as (1) a pathogenic variant,
(2) a likely pathogenic variant of uncertain significance (VUS),
(3) a VUS, or (4) a likely benign VUS. It was decided not to catego-
rize any variants as definitely benign, given that all variants listed
as disease-causing mutations in HGMD have been reported in the
literature at least once.
Criteria for each category were discussed and developed during
several meetings of the NEXT Medicine RORC. The criteria
included the allele frequency of the variant, segregation evidence,
the number of affected individuals found with the variant, and
status as a de novo mutation. For a variant to be assigned to cate-
gories other than VUS or likely benign VUS, its allele frequency
was required to be less than that expected for the disease, con-
sidering the pattern of inheritance and penetrance. If a variant is
present in the general population more commonly than would
be expected given the frequency of the associated disease, it is un-
likely that the variant causes a high-penetrance phenotype.
Cosegregation of a variant was also considered a criterion in deter-
mining pathogenicity. A probability of the observed cosegregation3, 2013
Table 2. Variant Classification Criteria
Variant Type Classification Criteria
Pathogenic allele frequency of variant below cutoffa
AND
segregation in at least two unrelated familiesb
OR
segregation in one family and identified in
at least three unrelated affected individualsc
OR
segregation in one family and at least one
de novo event in triod
OR
protein truncation where this event is
known to cause disease
Likely pathogenic
VUS
allele frequency of variant below cutoff
AND
identified in at least three unrelated individuals
OR
segregation in one family
OR
at least one de novo event in trio
VUS allele frequency of variant below cutoff
AND
identified in fewer than three unrelated affected
individuals
OR
no segregation studies
OR
no de novo events in a trio
Likely benign VUS allele frequency of variant well above cutoff
AND/OR
seen in combination with a known pathogenic
mutation
aBased on disease frequency and inheritance pattern (see ‘‘Criteria for Classifi-
cation of Variants’’).
bDefined as probability of consistent sharing in the family of%1/16.
cDependent on allele frequency.
dMutation identified as de novo dominant in an affected offspring of unaf-
fected individuals.by random chance of 1/16 or less (equivalent to a probability of
0.0625) was decided upon by the NEXT Medicine RORC as a con-
servative cutoff. The group decided that the presence of only one
affected individual with the rare variant was not sufficient to assert
causality; however, more than one unrelated individual reported
in the literature would considerably strengthen the evidence of a
variant’s pathogenicity. Thus, the criterion of three or more unre-
lated affected individuals with the rare variant of interest was
decided upon. Finally, if a variant was described in the literature
as de novo, this increased suspicion that the variant was patho-
genic.
Additionally, in the NEXT Medicine project, we chose not to
return VUSs to participants for IFs in genes unrelated to the pre-
senting condition. Both the need for stringent evidence of patho-
genicity and the decision not to return an IF VUS derive from the
low prior probability that a participant has a pathogenic variant
when incidental findings are considered. This is in contrast to
an individual who presents clinically with a relevant disorder.
For example, a BRCA1 VUS is more likely to be pathogenic in a
woman with breast or ovarian cancer and no known pathogenic
variant than in a woman without a personal or family history of
related cancers.
Data from multiple sources were evaluated for determining the
potential pathogenicity of each variant. Primary literature was
compiled from articles cited by the Human Genome Mutation
Database (HGMD Professional 2012.34) curators, PubMed, andThe AmericGoogle. Variant classifications from databases including the Lei-
den Open Variant Database, InSiGHT, dbSNP, and the Breast Can-
cer Information Core (BIC) were also examined. The primary data
from these sources and the allele frequency supplied by the NHLBI
Exome Variant Server (EVS) were used for classifying variants
according to the scheme detailed in Table 2.Participants and Variant Selection
One thousand participants, 500 of European ancestry and 500 of
African ancestry, were randomly selected from the 6,503 individ-
uals in the NHLBI ESP. The variant data are derived from partici-
pants from 18 well-phenotyped populations. Details regarding
these populations can be found on the ESP website. Ancestry
was inferred from analysis of principal components.5,6 These par-
ticipants’ exome variants were reviewed for the 114 genes of inter-
est (Table 1) for each variant listed as disease causing in HGMDand
any disruptive mutations expected to cause disease (truncating
variants) but not identified by HGMD as disease-causing muta-
tions. However, these ‘‘disease-causing’’ variants were assumed to
be benign for rare autosomal-dominant (AD) disorders when the
minor allele frequency (MAF) was >0.005 because they were too
common to be highly penetrant pathogenic variants given the dis-
ease frequency.Expert Variant Review
Each reported potential pathogenic variant listed as disease
causing in HGMD was assigned to one of 19 expert reviewers.
These reviewers were all geneticists: 14 were clinical geneticists,
genetic counselors, or certified molecular geneticists, and the
remainder had significant relevant genomic expertise. Each
reviewer was charged with (1) determining whether the allele fre-
quency was less than a disease-specific maximum frequency and
(2) reviewing the primary literature, including all papers cited by
HGMD, in order to document these data and determine whether
the evidence met the specific pathogenicity criteria (Table 2).
The maximum allowable allele frequencies for each disease were
calculated under a very conservativemodel, including the assump-
tion that the given disorder was wholly due to that variant. When
disease frequencies were unknown, they were conservatively over-
estimated. Reviewers were provided with total MAF and ancestry-
specific allele frequencies. Ten percent (24 of 239) of the variants
were independently double reviewed for pathogenicity, including
both the allele frequency and the primary literature review, for
quality control. In all cases, the double reviewers were one of
two senior scientist clinical geneticists, each with over 10 years
of clinical expertise. Each reviewer filled out a spreadsheet that
summarized the findings relevant to the pathogenicity categoriza-
tion. The spreadsheet of all 239 unique variant classifications was
also reviewed by a genetic counselor for ensuring that the classifi-
cation matched the evidence summarized by the reviewer. Any
reviewer could nominate a difficult-to-categorize variant for com-
mittee review. Thirteen available reviewers met as a group to re-
view the difficult-to-categorize variants and decide on the final
pathogenicity. This work was accomplished on data without iden-
tifiers or phenotypes, so genotype-phenotype correlations were
not possible.
Each reviewer was also asked to record the number of minutes it
took to review each variant andmake a conclusion. The number of
minutes of review time was reduced when electronic links were
available for the primary literature cited by HGMD. A genetic
counselor was tasked with locating and sending to reviewers anyan Journal of Human Genetics 93, 631–640, October 3, 2013 633
reference that was not available through local sources. The time to
locate a reference, time to train reviewers, and time for the com-
mittee to meet were not captured in the variant-review time-tak-
ing measures.
Variants that were disruptive, predicted to cause protein trunca-
tion, and not listed as disease causing in HGMD were also identi-
fied. These variants were further considered if the gained stop
codon was in the first 90% of the amino acid sequence. The
literature was reviewed for investigating whether truncating mu-
tations are causative of the disease phenotypes for such genes.
Literature and ClinVar were both reviewed in the search for prior
reports of these variants and data regarding pathogenicity.Results
One hundred and fourteen actionable genes were identi-
fied for return of results and are listed in Table 1. This list
includes 88 AD, 4 X-linked, and 22 autosomal-recessive
(AR) diseases. In the 1,000 exomes, after exclusion of vari-
ants withMAF> 0.005, 239 unique variants occurring a to-
tal of 585 times were identified as potentially pathogenic
in these loci on the basis of their classification as ‘‘disease
causing’’ in HGMD. Among the 239 unique putatively dis-
ease-causing variants, 230 were in AD loci, three were in
X-linked loci, and six were in AR loci. The AR variants
were three pairs of variants within single individuals, given
that carrier status was not included for reporting. Five
disruptive mutations not listed as disease causing in
HGMD were also identified. These disruptive mutations
were all in AD loci.
Of the 239 unique variants, 72 (30.1%) had an allele fre-
quency above the disease-specific frequency cutoff in the
NHLBI ESP 6,500-exome data set. Thus, these occurred
too frequently in the sample to be considered potentially
pathogenic for the relevant disorder; however, the litera-
ture supporting the disease-causing HGMD status of these
72 variants was still reviewed. None of these 72 were classi-
fied as pathogenic or likely pathogenic. Each of the 239 var-
iants was observed between one and ten times in the 1,000
subjects; 123 of these 239 were seen only once. Fifteen of
the 16 pathogenic or likely pathogenic variants for domi-
nant diseases were observed once in these 1,000 subjects,
and one variant was seen in two subjects. Given that
51.4% (123/239) of these variants were seen only once,
these 15 out of 16 represent a significant excess of patho-
genic variants of low MAF (binomial p value < 0.0004).
Notably, some variants identified in the literature as be-
ing found in multiple individuals with a disease were too
common to be highly penetrant pathogenic alleles. Exam-
ples include the PKP2 missense mutations c.1759G>A
(p.Val587Ile) (rs146102241) and c.419C>T (p.Ser140Phe)
(rs150821281), each of which was identified in five Euro-
pean-descent participants in our cohort and whose fre-
quencies in 4,200 European-descent participants in the
ESP were 0.005 and 0.003, respectively. These variants
have been associated with arrhythmogenic right ventricu-
lar cardiomyopathy (MIM 609040).7,8 This disorder is634 The American Journal of Human Genetics 93, 631–640, Octoberexpected to affect fewer than 1 in 1,000 individuals, indi-
cating an expected MAF of ~0.001. Similarly, two Euro-
pean-descent participants had an identical putative TP53
mutation (causing Li-Fraumeni syndrome [MIM
151623]).9 However, the frequency of this variant
(c.847C>T [p.Arg283Cys]) (rs149633775) in the ESP was
0.0004, and 2 of our 500 European-descent participants
were carriers (for a frequency of 0.001). The prevalence of
Li-Fraumeni syndrome is estimated to be 1 in 20,000.10
Although these could be low-penetrance alleles for over-
lapping phenotypes, they could also be benign alleles
found in affected individuals by chance. The availability
of allele frequencies from sources such as the EVS, with
large sample sizes, greatly improves our ability to classify
such alleles that are too common to be highly penetrant
pathogenic mutations.
Literature and stringent criteria (Table 2) found that of
the 239 unique HGMD disease-causing variants identified,
only 16 unique AD variants (in 17 participants) and one AR
variant pair were pathogenic or likely pathogenic. Thus,
1.8% (18 of 1,000) of the participants analyzed were found
to have pathogenic or likely pathogenic actionable vari-
ants also listed as disease-causing mutations in HGMD.
These variants are listed in Tables 3 and 4. The classifica-
tions of all 239 variants are included in Table S1, available
online. The eight participants with confirmed pathogenic
(versus likely pathogenic) mutations included three with
increased risk of breast and ovarian cancer (MIM 604370,
caused by BRCA1 mutations, or MIM 612555, caused by
BRCA2 mutations), one with a mutation in LDLR, associ-
ated with familial hypercholesterolemia (MIM 614337),
one with a mutation in PMS2, associated with Lynch
syndrome (MIM 614337), and two with mutations in
MYBPC3, associated with hypertrophic cardiomyopathy
(MIM 115197), as well as one person with two SERPINA1
mutations, associated with the autosomal-recessive disor-
der alpha-1-antitrypsin deficiency (MIM 613490). The
phase of the SERPINA1 mutations could not be addressed
with these data, but compound heterozygosity is most
likely given that the variants are unlikely to have occurred
on the same ancestral haplotype.
The nominated yield of variants listed as disease causing
in HGMD varied by ancestry group. Approximately 71.5%
(419/585) of the total variants were identified in individ-
uals of European descent, 25.0% (146/585) were identified
in individuals of African descent, and 3.4% (20/585) were
identified in the 16 individuals of Ashkenazi Jewish
descent (Table 5). Of the 239 unique variants, only 94
(39.3%) were found in those of African descent. This signif-
icantly differs from the expected 50%, given that 500 of
the 1,000 subjects were of African descent (binomial test
p ¼ 0.0006). Eighteen participants had likely pathogenic
or pathogenic mutations, and of these, only three
(16.7%) were of African descent; again, this is significantly
less than the expected 50% (binomial test p ¼ 0.0038).
All 239 unique variants listed as disease causing in
HGMD had their spreadsheet of criteria reviewed by a3, 2013
Table 3. Pathogenic Actionable Variants Listed as Disease Causing in HGMD
Gene Variant
Reference
SNP ID
Primary Associated
Condition(s) Inheritance Ancestry (n)
BRCA1
(MIM 113705)
NP_009225.1: p.Arg1699Trp
NM_007294.3: c.5095C>T
NC_000017.10: g.41215948G>A
rs55770810 hereditary breast and ovarian
cancer (MIM 604370)
AD E (1)
BRCA1a
(MIM 113705)
NP_009225.1: p.Glu908*
NM_007294.3: c.2722G>T
NC_000017.10: g.41244826C>A
rs80356978 hereditary breast and ovarian
cancer (MIM 604370)
AD E (1)
BRCA2a
(MIM 600185)
NP_000050.2: p.Tyr1894*
NM_000059.3: c.5682C>G
NC_000013.10: g.32914174C>G
rs41293497 hereditary breast and ovarian
cancer (MIM 612555)
AD E (1)
LDLR
(MIM 143890)
NP_000518.1: p.Ser99*
NM_000527.4: c.296C>G
NC_000019.9: g.11213445C>G
- familial hypercholesterolemia
(MIM 143890)
AD E (1)
MYBPC3
(MIM 600958)
NP_000247.2: p.Ala833Thr
NM_000256.3: c.2497G>A
NC_000011.9: g.47359047C>T
rs199865688 hypertrophic cardiomyopathy
(MIM 115197)
AD E (1)
MYBPC3
(MIM 600958)
NP_000247.2: p.Arg502Trp
NM_000256.3: c.1504C>T
NC_000011.9: g.47364249G>A
- hypertrophic cardiomyopathy
(MIM 115197)
AD E (1)
PMS2
(MIM 600259)
NP_000526.1: p.Ser46Ile
NM_000535.5: c.137G>T
NC_000007.13: g.6045549C>A
rs121434629 Lynch syndrome (MIM 614337) AD E (1)
SERPINA1
(MIM 107400)
NP_000286.3: p.Glu366Lys
NM_000295.4: c.1096G>A
NC_000014.8: g.94844947C>T
rs28929474 alpha 1 antitrypsin deficiency
(Z allele) (MIM 613490)
ARb A (1)
SERPINA1
(MIM 107400)
NP_000286.3: p.Glu288Val
NM_000295.4: c.863A>T
NC_000014.8: g.94847262T>A
rs17580 alpha 1 antitrypsin deficiency
(S allele) (MIM 613490)
ARb A (1)
Abbreviations are as follows: AD, autosomal dominant; AR, autosomal recessive; E, European; and A, African.
aBased on classification reported by Myriad in the Breast Cancer Information Core database.
bFound in the same individual.single genetic counselor and then discussed with a senior
medical geneticist; this led to the movement of two vari-
ants among the classes pathogenic, likely pathogenic,
and all other. One was upgraded from VUS to likely patho-
genic, and one was downgraded from pathogenic to VUS.
Of the 28 variants wholly double reviewed, three were
discordant among the classes pathogenic, likely patho-
genic, and all other. One was downgraded from pathogenic
to VUS, one was downgraded from likely pathogenic VUS
to VUS, and one was upgraded from VUS to likely patho-
genic VUS. These data demonstrate that even expert re-
viewers can interpret the literature differently.
The allele frequency and literature review of the 239
unique variants took a total of 5,536 min (92.27 hr).
Thus, the average time spent reviewing each variant was
23 min (range ¼ 1–135 min) for just the literature review
and categorization step, excluding the time to generate
the list of potential variants, collect the references, and
resolve questionable variants in a group setting. This
time was substantially less than that required if all 585 var-
iants had been reviewed on a per person basis.
The five predicted disruptive mutations that were not
listed in HGMD as disease-causing mutations are listed in
Table 6. These mutations were located within the first
90% (18%–57%) of the transcript and most likely lead toThe Americnonsense-mediated mRNA decay. The BRCA2 variant was
classified as pathogenic in ClinVar. The remaining variants
were not found in ClinVar; however, return might be
warranted because the premature truncations are likely
pathogenic, although we did not find literature or ClinVar
entries specifically identifying TMEM43 truncations as
pathogenic. Two additional predicted disruptive muta-
tions were identified; however, these stops occurred in
the final 10% of the transcript and were thus not included
as likely pathogenic, given that such transcripts might not
be affected by nonsense-mediated decay and might be
functional. Notably, the disruptive mutations identified
with a gained stop codon, as opposed to the HGMD listed
disease-causing mutations from the literature, were more
evenly split with three of the five mutations identified in
the African-descent group.Discussion
This work has several important findings. First, only 23
participants were identified as having pathogenic or likely
pathogenic mutations in 114 medically actionable genes
whose pathogenic mutations might not present clinically
until adulthood (Table 7). In 18 of the participants, thesean Journal of Human Genetics 93, 631–640, October 3, 2013 635
Table 4. Likely Pathogenic Actionable Variants Listed as Disease Causing in HGMD
Gene Variant
Reference
SNP ID
Primary Associated
Condition(s) Inheritance Ancestry (n)
CACNB2
(MIM 600003)
NP_963884.2: p.Ser143Phe
NM_201590.2: c.428C>T
NC_000010.10: g.18789874C>T
rs150528041 Brugada syndrome
(MIM 601144)
AD E (1)
CDH1
(MIM 192090)
NP_004351.1: p.Val832Met
NM_004360.3: c.2494G>A
NC_000016.9: g.68867247G>A
rs35572355 hereditary diffuse gastric
cancer (MIM 137215)
AD A (1)
DSG2
(MIM 125671)
NP_001934.2: p.Gly812Cys
NM_001943.3: c.2434G>T
NC_000018.9: g.29125783G>T
rs121913010 arrhythmogenic right ventricular
cardiomyopathy (MIM 610193)
AD E (1)
KCNQ1
(MIM 607542)
NP_000209.2: p.Thr600Met
NM_000218.2: c.1799C>T
NC_000011.9: g.2869001C>T
rs34516117 long QT syndrome (MIM 192500) AD A (1)
LDLR
(MIM 143890)
NP_000518.1: p.Ala606Ser
NM_000527.4: c.1816G>T
NC_000019.9: g.11227645G>T
rs72658865 familial hypercholesterolemia
(MIM 143890)
AD E (1)
MYBPC3
(MIM 600958)
NP_000247.2: p.Glu619Lys
NM_000256.3: c.1855G>A
NC_000011.9: g.47362731C>T
rs200352299 hypertrophic cardiomyopathy
(MIM 115197)
AD E (2)a
MYBPC3
(MIM 600958)
NP_000247.2: p.Gly490Arg
NM_000256.3: c.1468G>A
NC_000011.9: g.47364285C>T
rs200625851 hypertrophic cardiomyopathy
(MIM 115197)
AD E (1)
SCN5A
(MIM 600163)
NP_932173.1: p.Thr1304Met
NM_198056.2: c.3911C>T
NC_000003.11: g.38603958G>A
rs199473603 long QT syndrome (MIM 603830) AD E (1)
TNNT2
(MIM 191045)
NP_001001430.1: p.Arg278Cys
NM_001001430.1: c.832C>T
NC_000001.10: g.201328373G>A
rs121964857 dilated and hypertrophic
cardiomyopathy (MIM 601494
and 115195)
AD E (1)
Abbreviations are as follows: AD, autosomal dominant; E, European; and A, African.
aFound in one participant of Ashkenazi descent.pathogenic and likely pathogenic variants were identified
through classification in HGMD as disease-causing muta-
tions, and five were identified via predicted premature
truncations. Second, the vast majority of variants classified
by HGMD as disease causing did not meet rigorous criteria
to be classified as high-penetrance pathogenic mutations.
Of the 239 unique variants classified by HGMD as disease
causing, only 7.5%—16 unique AD variants in 17 individ-
uals and two unique AR variants in the same individual—
were found to be pathogenic or likely pathogenic. Third,
allele frequency was a strong predictor of pathogenicity.
Whereas 51.4% (123/239) of the variants evaluated
were seen only once in the 1,000 participants, 15 of the
16 pathogenic or likely pathogenic AD variants were
only seen once in the cohort. All HGMD variants classified
as pathogenic or likely pathogenic had an allele
frequency % 0.104%. Indeed, no adequate database
currently exists for the purpose of rigorously identifying
pathogenic mutations at a level sufficient for clinical re-
turn. Inclusion of filters on allele frequencies is expected
to improve classification. Fourth, there was a deficit of
pathogenic variants identified in the African-descent par-
ticipants, which most likely reflects the deficit of genetic
literature on variants in non-European populations. Fifth,
review of any one unique variant took, on average, 23 min
of expert review time when references were provided.636 The American Journal of Human Genetics 93, 631–640, OctoberThe ACMG recently made recommendations for manda-
tory return of variants related to 56 genes for children or
adults.1 Our 114-gene list overlaps the ACMG list by 52
genes relevant to adults (Table 1). The four genes on the
ACMG list that do not overlap with our gene list (RB1
[MIM 614041], TSC1, TSC2, and WT1 [MIM 607102]) are
related to conditions with pediatric onset only and do
not apply to our adult population. Of the 23 participants
we identified with pathogenic or likely pathogenic vari-
ants, 20 (8 with pathogenic and 12 with likely pathogenic
mutations) had variants from the ACMG gene list,
including BRCA1, BRCA2, CACNA1S, DSC2, DSG2,
KCNQ1, LDLR, MYBPC3, PMS2, RYR1, SCN5A, TMEM43,
and TNNT2. Three participants had pathogenic or likely
pathogenic variants in other genes that our committee
considered actionable: CACNB2, CDH1, and SERPIN1A.
Thus, the ACMG list successfully identifies the more com-
mon actionable genes. The cohorts that provided the sam-
ples we analyzed must decide, in consultation with their
participants and other stakeholders, whether and how
sequencing results will be offered to participants. The
data on which these analyses were based are available to
the contributing cohorts.
Fault for misclassification of variants in HGMD falls
largely on the weak primary literature rather than HGMD
extraction errors. In one case, a paper proposed that a3, 2013
Table 5. Number and Percent of Variants from HGMD by Ancestry
African Descent European Descent Ashkenazi Descent Total
Participants 500 (50.0%) 484 (48.4%) 16 (1.6%) 1,000
HGMD ‘‘disease-causing’’ variants 146 (25.0%) 419 (71.6%) 20 (3.4%) 585
Unique HGMD ‘‘disease-causing’’ variants 94 (39.3%) 125 (52.3%) 20 (8.4%) 239
Participants with pathogenic variants 1 (12.5%) 7 (87.5%) 0 8
Participants with likely pathogenic variants 2 (20%) 7 (70%) 1 (10%) 10TP53 VUS with aMAF of 0.001 worsened the phenotype in
an affected individual with a separate known pathogenic
mutation, ignoring that the known pathogenic variant
segregated with the disease on the maternal side and that
the VUS was inherited from an apparently unaffected
father.11 Similarly, a second paper proposed that a pater-
nally inherited FBN1 VUS with a MAF of 0.001, which
was found in a proband with a maternally inherited
known FBN1mutation, contributed to the proband’s skel-
etal features of the phenotype.12 These reports should not
have concluded that these variants were pathogenic. These
VUSs were found in individuals with known pathogenic
mutations, and their allele frequencies make them too
common to be the cause of their associated diseases.
More often, the unsupported conclusions rely on weak
data such as allele frequency differences in small numbers
of cases and controls or the simple identification of a VUS
in an affected participant. Going forward, access to the
allele frequencies for these variants in the 1000 Genomes
Project or through the NHLBI EVS will help identify
polymorphisms that occur too frequently to be highly
penetrant pathogenic mutations. Occasionally, errors
compound one another, e.g., a second publication cites
an initial weak report.13 Although HGMD is certainly
nonspecific in its classification of a variant as disease
causing, it has an important role in being oversensitive.
This allows those interested in pathogenicity to use
HGMD as a source of potentially pathogenic variants to re-
view. However, a well-populated source of more specific
data is a requirement for the reliable, efficient, and wide-
spread application of genomic medicine.
With regard to the reporting of pathogenic mutations in
the literature, we endorse standards that could aid in infor-
matic and manual review for determining the pathoge-
nicity of variants. Clinical laboratories and many journals
have adopted the variant nomenclature proposed by the
Human Genome Variation Society. Additionally, re-
searchers should detail all segregation data in the pedi-
gree(s), including affected and unaffected individuals,
along with the likelihood that the segregation happened
by chance rather than rely on uninformative statements
such as ‘‘the variant segregated with the disease.’’ For
example, co-occurrence of a variant with disease in an
affected mother and proband pair would be described as
having a 50% probability of happening by chance. Report-
ing information on the genotype and the affected status ofThe Americthe grandparent from whom a dominant allele arose and
all other tested individuals would allow quantification of
the probability that the segregation occurs by chance.
The literature is beginning to address the issue of action-
able IFs. A prior report14 identified eight pathogenic cancer
syndrome variants in 572 ClinSeq participants; however,
seven of these were BRCA1 or BRCA2 mutations, and
four were in participants of Ashkenazi Jewish descent.
That paper surveyed the literature for pathogenic variants,
but other than having aMAF< 0.015, it only specified gen-
eral (e.g., segregation) rather than quantitative criteria for
inclusion. Of the 572 ClinSeq participants, 97 (17%)
were Ashkenazi. Excluding these, 3 of 475 (0.6%) non-
Ashkenazi participants had such pathogenic cancer vari-
ants. Only 16 of the 500 European-descent participants
in the current report, or ~3.2% of the total sample, were
Ashkenazi, and only 1 out of the 23 (4.3%) participants
with pathogenic or likely pathogenic variants was Ashke-
nazi (Tables 3, 4, and 5). To our knowledge, this MYBPC3
c.1855G>A (p.Glu619Lys) (rs200352299) variant is not
an Ashkenazi founder mutation. Overall, 5 of our 1,000
participants had pathogenic variants, and another had a
likely pathogenic actionable variant relevant to cancer,
similar to the ClinSeq14 experience (after the decreased
numbers of Ashkenazi participants are considered).
An analysis by Xue et al. of 179 participants from the
1000 Genomes Project estimated that each individual
would have on average two disease-causing mutations.15
However, this work did not limit itself to highly penetrant,
actionable variants. Further, although HGMD classifica-
tion was reviewed in the primary literature, a single source
or functional-study evidence appears to have been suffi-
cient for classification as a pathogenic mutation. Given
that Xue et al.’s goal was estimation of pathogenic-variant
load and our goal was high confidence that returned vari-
ants would be clinically useful, it is understandable that
they used a less stringent test than the criteria used here.
As in the current study, these authors emphasize the
need for better databases of disease alleles. This under-
scores our conclusion that the primary literature on which
HGMD draws requires more stringent criteria to support
that an allele is disease causing.
Variants that are pathogenic in individuals of European
descent are expected to be pathogenic in participants of
other ancestry groups,16 but variants that do not occur in
those of European descent are understudied. Fifty percentan Journal of Human Genetics 93, 631–640, October 3, 2013 637
Table 6. Disruptive Variants Not Listed as Disease Causing in HGMD
Gene
DNA
Change
Protein
Change
Amino Acid
Length
Reference
SNP ID Primary Associated Condition(s) Inheritance Ancestry (n)
BRCA2a
(MIM 600185)
c.5855T>A p.Leu1952* 3,419 - hereditary breast and ovarian
cancer (MIM 612555)
AD A (1)
CACNA1S
(MIM 114208)
c.2707G>A p.Arg903* 1,874 - malignant hyperthermia
(MIM 601887)
AD E (1)
DSC2
(MIM 125645)
c.663A>T p.Tyr221* 848; 902 rs145476705 arrhythmogenic right ventricular
dysplasia (MIM 610476)
AD A (1)
RYR1
(MIM 180901)
c.2662C>T p.Gln888* 5,039; 5,034 rs141838633 malignant hyperthermia
(MIM 145600)
AD A (1)
TMEM43b
(MIM 612048)
c.578C>A p.Ser193* 401 rs140380494 arrhythmogenic right ventricular
dysplasia (MIM 604400)
AD E (1)
Abbreviations are as follows: AD, autosomal dominant; E, European; and A, African.
aListed as pathogenic in ClinVar (submission accession number RCV000031583.1).
bNo literature citing truncations in TMEM43 as causative of arrhythmogenic right ventricular dysplasia was identified. No truncating mutations in TMEM43 were
present in HGMD or ClinVar.of our study cohort was of European descent, but 83% (15/
18) of the participants were found to have potentially
returnable results from this group with the use of HGMD
for identifying disease-causing mutations. The deficit in
likely pathogenic or pathogenic variants identified in the
African-descent group, which is expected to have more
variation overall, is probably due primarily to the under-
representation of these participants in the literature17-
based reporting for disease variants; however, other
reasons have been postulated.18 When the five disruptive
mutations not listed as disease causing in HGMD were
added, a total of 74% (17/23) of subjects with returnable
results were of European descent, which remains less
than 50% (binomial p ¼ 0.012; Table 7). The result is
that genomic testing is more informative for those of Euro-
pean descent, causing a health-care disparity that is best
addressed by active inclusion of non-European-descent in-
dividuals in studies that characterize variants.
Our study informs the types of efforts required of a clin-
ical genomics lab to call pathogenic variants. It also
informs the debate about return of IFs to research partici-
pants. Although there is some consensus that researchers
should return the genetic IFs that they identify to their
interested participants,19,20 there is a debate about whether
investigators are obligated to actively look for such
results.21 These data suggest that the search for and com-
petent interpretation of genomic variants are not incon-
sequential tasks.
Limitations of the current work include (1) the study of
only 500 each of European- and African-decent partici-
pants, (2) the exclusion of pediatric-onset conditions, (3)
the reliance on HGMD and disruptive mutations for iden-
tifying potentially pathogenic mutations, and (4) the lack
of access to phenotypes. These results might not be gener-
alizable to all ethnic groups, but because European-decent
groups are studied the most, the search for known patho-
genic mutations might be most fruitful in this racial group.
A larger number of possibly pathogenic actionable findings638 The American Journal of Human Genetics 93, 631–640, Octoberthan we describe here might be identified in infants and
young children, given that we excluded genes for condi-
tions that would be uniformly diagnosed in childhood.
We did include pediatric-onset conditions that might
remain undiagnosed into adulthood, e.g., mild phenylke-
tonuria (MIM 261600). Finally, it is possible that some
pathogenic variants were missed because of their not being
labeled as disease causing in HGMD or disruptive. How-
ever, it is unlikely that variants not identified by HGMD
would meet our strict criteria for pathogenicity; rather,
HGMD is oversensitive and not specific. Our results sug-
gest that we did not markedly overcall or undercall vari-
ants. For example, LDLR mutations are expected to be
found in 1/500 individuals,22 and we found two patho-
genic or likely pathogenic mutations in 1,000 people.
Similarly, we found one pathogenic mutation for Lynch
syndrome and three BRCA1 or BRCA2 mutations,23,24
which are also each expected to be found in 1/350 to
1/1,000 people. Use of ESP data might have enriched for
LDLR or SERPINA1 mutations, given the inclusion of
subjects with atherosclerosis and chronic obstructive pul-
monary disease, although pathogenic variants in these
conditions occur at the expected population frequencies.
All other pathogenic or likely pathogenic variants appear
unrelated to the ascertainment of the ESP cohorts.
The term IF is imperfect for describing genome or exome
findings that are not related to the condition for which the
test was ordered. IFs are generally considered to be un-
avoidable consequences of a test or clinical evaluation.
However, a genomic test need not query for results in genes
unrelated to the testing purpose, and indeed, these types of
findings might be actively sought.25 One alternative term,
‘‘secondary findings,’’ has also been criticized; the term sec-
ondary has the specific meaning in medicine of being due
to another cause, for example, secondary hyperparathy-
roidism as a response to hypocalcemia. Further, secondary
might suggest to a patient that the results are less impor-
tant than they truly are. ‘‘Unanticipated findings26’’ has3, 2013
Table 7. Number of Individuals with Pathogenic or Likely
Pathogenic Variants by Ancestry
Classification
European
Ancestry
African
Ancestry
Pathogenic variants from HGMD 7/500 1/500
Likely pathogenic variants from HGMD 8/500 2/500
Disruptive pathogenic variants 0/500 1/500
Disruptive likely pathogenic variants 2/500 2/500
Total 17/500 6/500been criticized given that we do expect, and should plan
for, such results. Reflecting on similarities to other types
of medical opportunistic screening, ‘‘opportunistic find-
ings’’ has been suggested to reflect that extra steps are
required for identifying these findings but has also been
criticized because of a perceived negative connotation of
the word opportunistic. ‘‘Unrelated findings’’ has also
been suggested27 but does not fully capture the concept
and does not have broad recognition. We chose to use
the term IFs here given that it was the preferred term in
the recent ACMG paper1 and is commonly used in the
genomics literature. Over time, consensus might develop
around an alternative term for these genomic findings,
such as ‘‘ancillary,’’ but there is no commonly used or
readily understandable alternative at the present time.
In summary, we found that ~3.4% of European-descent
adults and ~1.2% of African-descent adults can be expected
to have actionable highly penetrant pathogenic or likely
pathogenic mutations identified by exome sequencing at
this time. Twelve of the 1,000 participants had pathogenic
mutations in genes for which the ACMG recommends
mandatory review and return of IFs to adults. We suggest
that consistent criteria should be developed for the report-
ing of pathogenic variants and that these criteria should be
more stringent for IFs, where the prior probability that a
variant is pathogenic is lower than for genes related to
the indication for the test. Current databases do not
adequately report pathogenicity for large numbers of vari-
ants, and these reviews are time consuming. Current liter-
ature also identifies fewer pathogenic variants in those of
African descent, most likely because of the underrepresen-
tation of these participants in clinical and research reports.
Finally, we endorse standard reporting formats for patho-
genic variants to aid in literature review.Supplemental Data
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